NICOLE SHEN: Open Payments
NPI 1073856027 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,405 in 45 payments from 14 companies in 2025. Trend: 2023 $1,439 · 2024 $2,843 · 2025 $1,405
Food & beverage: $1,405
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 3 | $212 |
| PFIZER INC. | 8 | $210 |
| Madrigal Pharmaceuticals | 4 | $182 |
| ABBVIE INC. | 10 | $180 |
| Boston Scientific Corporation | 3 | $153 |
| CONMED Corporation | 2 | $139 |
| Janssen Biotech, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
Products named: DUPIXENT, REZDIFFRA, CONMED BILIARY, EXALT Model D, VELSIPITY, XELJANZ, TREMFYA, RINVOQ.
Industry payments across MO — which companies pay providers there.
